News and Announcements
Crypto (DeFi) Focused Systematic Investment Fund and Platform with a 90% Customer Retention Rate | Average Return of 23.10%
- Published December 16, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“Having a systematic approach to investing gives you conviction and tools to use when markets get volatile. Using machines to their fullest—while augmenting that with human intelligence, can be an incredible edge.”
Charles Meaden, CEO & Co-Founder – Gembot
Executive Summary
Gembot is a FinTech and Fund with an AI investment platform that democratises investment strategies and tools for consumers. Gembot focuses on small and mid-cap US equities, derivatives, and crypto, specifically DeFi. Since its inception, Gembot has averaged a 23.10% return per 120-day cycle.
Investment Highlights
-
The company’s highest return on a 120-day fund is 94.73% after fees.
-
Gembot has closed seventeen 120-day funds with a win rate of 83.25% and an average return of 23.10%.
-
The company’s customer retention rate over 18 months is 90%.
-
Its team and board are experienced in technology. Gembot’s founder has sold a gaming platform and the lead investor and Chair of the Board has invested in four other technology companies.
Investment Offering
Gembot is raising capital through a debt offering and has already raised $2.3M in equity.
Company Updates
The RBA Just Validated the Shift to Private Credit
With the RBA’s latest decision confirming the ‘higher for longer’ environment, sophisticated investors are rotating capital from rate-sensitive public markets into private credit for superior, lower-volatility yields. The era of cheap money is over, making private credit a necessary multi-year positioning decision.
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Backed By Leading Investment Groups and Family Offices
